Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: PAM

Gene summary for PAM

Gene summary.

Gene information	Species	Human
	Gene symbol	PAM
	Gene ID	5066
	Gene name	peptidylglycine alpha-amidating monooxygenase
	Gene Alias	PAL
	Cytomap	5q21.1
	Gene Type	protein-coding
	GO ID	GO:0000003
	UniProtAcc	P19021

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
5066	PAM	GSM4909281	Human	Breast	IDC	4.72e-26	7.25e-01	0.21
5066	PAM	GSM4909285	Human	Breast	IDC	1.30e-20	6.12e-01	0.21
5066	PAM	GSM4909286	Human	Breast	IDC	3.52e-11	-1.61e-01	0.1081
5066	PAM	GSM4909287	Human	Breast	IDC	9.18e-03	3.09e-01	0.2057
5066	PAM	GSM4909290	Human	Breast	IDC	3.17e-04	-1.62e-01	0.2096
5066	PAM	GSM4909294	Human	Breast	IDC	6.42e-09	-1.43e-01	0.2022
5066	PAM	GSM4909296	Human	Breast	IDC	5.78e-03	-2.23e-03	0.1524
5066	PAM	GSM4909297	Human	Breast	IDC	2.74e-03	-1.19e-01	0.1517
5066	PAM	GSM4909301	Human	Breast	IDC	2.79e-03	-1.08e-01	0.1577
5066	PAM	GSM4909304	Human	Breast	IDC	2.24e-02	-1.18e-01	0.1636
5066	PAM	GSM4909308	Human	Breast	IDC	3.04e-09	4.15e-01	0.158
5066	PAM	GSM4909311	Human	Breast	IDC	4.84e-12	-6.92e-03	0.1534
5066	PAM	GSM4909312	Human	Breast	IDC	1.09e-03	-5.47e-02	0.1552
5066	PAM	GSM4909315	Human	Breast	IDC	2.51e-08	-1.51e-01	0.21
5066	PAM	GSM4909319	Human	Breast	IDC	8.04e-10	-1.59e-01	0.1563
5066	PAM	GSM4909321	Human	Breast	IDC	5.17e-05	4.83e-02	0.1559
5066	PAM	NCCBC14	Human	Breast	DCIS	4.04e-02	-1.36e-01	0.2021
5066	PAM	NCCBC5	Human	Breast	DCIS	2.12e-03	-1.45e-01	0.2046
5066	PAM	P1	Human	Breast	IDC	4.05e-03	-1.49e-01	0.1527
5066	PAM	DCIS2	Human	Breast	DCIS	9.75e-50	3.99e-01	0.0085

Page: 1 2 3 4 5 6 7 8 9

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:001003822	Liver	HCC	response to metal ion	208/7958	373/18723	1.35e-07	2.56e-06	208
GO:0090305	Liver	HCC	nucleic acid phosphodiester bond hydrolysis	152/7958	261/18723	1.90e-07	3.46e-06	152
GO:00550882	Liver	HCC	lipid homeostasis	103/7958	167/18723	4.27e-07	7.18e-06	103
GO:004648611	Liver	HCC	glycerolipid metabolic process	215/7958	392/18723	4.54e-07	7.49e-06	215
GO:000941022	Liver	HCC	response to xenobiotic stimulus	248/7958	462/18723	6.47e-07	1.02e-05	248
GO:005105221	Liver	HCC	regulation of DNA metabolic process	198/7958	359/18723	7.62e-07	1.17e-05	198
GO:000166612	Liver	HCC	response to hypoxia	172/7958	307/18723	1.06e-06	1.59e-05	172
GO:00516071	Liver	HCC	defense response to virus	151/7958	265/18723	1.27e-06	1.85e-05	151
GO:01405461	Liver	HCC	defense response to symbiont	151/7958	265/18723	1.27e-06	1.85e-05	151
GO:003629312	Liver	HCC	response to decreased oxygen levels	179/7958	322/18723	1.29e-06	1.87e-05	179
GO:003428422	Liver	HCC	response to monosaccharide	131/7958	225/18723	1.32e-06	1.91e-05	131
GO:000863712	Liver	HCC	apoptotic mitochondrial changes	70/7958	107/18723	1.39e-06	2.01e-05	70
GO:007048212	Liver	HCC	response to oxygen levels	191/7958	347/18723	1.42e-06	2.03e-05	191
GO:004501711	Liver	HCC	glycerolipid biosynthetic process	143/7958	252/18723	3.27e-06	4.31e-05	143
GO:00447431	Liver	HCC	protein transmembrane import into intracellular organelle	29/7958	36/18723	3.42e-06	4.49e-05	29
GO:000974622	Liver	HCC	response to hexose	126/7958	219/18723	4.81e-06	6.06e-05	126
GO:005138421	Liver	HCC	response to glucocorticoid	90/7958	148/18723	5.18e-06	6.47e-05	90
GO:00066504	Liver	HCC	glycerophospholipid metabolic process	168/7958	306/18723	7.27e-06	8.62e-05	168
GO:004647411	Liver	HCC	glycerophospholipid biosynthetic process	121/7958	211/18723	9.12e-06	1.06e-04	121
GO:001082312	Liver	HCC	negative regulation of mitochondrion organization	36/7958	49/18723	1.08e-05	1.24e-04	36

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

PAM

SNV

Missense_Mutation

novel

c.371N>T

p.Gly124Val

p.G124V

P19021

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-5L-AAT1-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Hormone Therapy

letrozol

PAM

SNV

Missense_Mutation

rs752414913

c.2119C>T

p.Arg707Trp

p.R707W

P19021

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-A8-A09C-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

PAM

SNV

Missense_Mutation

rs771873156

c.2710N>A

p.Glu904Lys

p.E904K

P19021

protein_coding

tolerated(0.06)

benign(0.308)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

PAM

SNV

Missense_Mutation

c.239N>C

p.Arg80Pro

p.R80P

P19021

protein_coding

tolerated(0.95)

benign(0.007)

TCGA-BH-A0AW-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

carboplatin

PAM

SNV

Missense_Mutation

c.2333A>G

p.His778Arg

p.H778R

P19021

protein_coding

tolerated(0.34)

benign(0)

TCGA-C8-A1HK-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

PAM

SNV

Missense_Mutation

novel

c.2433N>C

p.Lys811Asn

p.K811N

P19021

protein_coding

tolerated(0.05)

benign(0.018)

TCGA-EW-A1PC-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

tamoxiphen

PAM

deletion

Frame_Shift_Del

novel

c.673delN

p.Asn226IlefsTer16

p.N226Ifs*16

P19021

protein_coding

TCGA-EW-A2FV-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

docetaxel

PAM

SNV

Missense_Mutation

novel

c.304C>T

p.His102Tyr

p.H102Y

P19021

protein_coding

deleterious(0)

possibly_damaging(0.899)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

PAM

SNV

Missense_Mutation

c.1175N>T

p.Ser392Leu

p.S392L

P19021

protein_coding

tolerated(0.07)

probably_damaging(0.992)

TCGA-Q1-A73O-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

PAM

SNV

Missense_Mutation

c.2038N>T

p.Pro680Ser

p.P680S

P19021

protein_coding

deleterious(0.05)

possibly_damaging(0.632)

TCGA-AA-3510-01

Colorectum

colon adenocarcinoma

Male

>=65

I/II

Unknown

Page: 1 2 3 4 5 6 7 8 9 10

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1